Published in JAMA on May 28, 2003
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol (2008) 3.63
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids (2007) 2.56
Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology (2009) 2.45
Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J (2008) 2.36
Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study. Osteoporos Int (2008) 2.27
Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ (2009) 1.99
Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation (2011) 1.88
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci U S A (2007) 1.83
Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke (2008) 1.80
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation (2005) 1.66
Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab (2009) 1.58
Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke (2009) 1.57
Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the Women's Health Initiative. J Womens Health (Larchmt) (2013) 1.57
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials (2007) 1.54
Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci (2009) 1.54
Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J Biomed Biotechnol (2011) 1.46
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol (2009) 1.45
Age-specific association of migraine with cryptogenic TIA and stroke: Population-based study. Neurology (2015) 1.42
Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain (2012) 1.40
Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here? Horm Behav (2008) 1.39
Blood biomarkers of ischemic stroke. Neurotherapeutics (2011) 1.34
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology (2009) 1.32
Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense). J Agric Food Chem (2005) 1.32
C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci U S A (2011) 1.31
Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS One (2010) 1.31
Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause (2011) 1.31
Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol (2007) 1.30
Neuroprotective effects of estrogens following ischemic stroke. Front Neuroendocrinol (2009) 1.28
Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci (2008) 1.25
Sex differences in stroke. Cerebrovasc Dis (2008) 1.24
Sex differences in stroke. J Cereb Blood Flow Metab (2012) 1.21
Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med (2008) 1.21
Dismembering the ethical physician. Postgrad Med J (2006) 1.21
Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats. Neurobiol Aging (2008) 1.20
Large mobile thrombus in non-atherosclerotic thoracic aorta as the source of peripheral arterial embolism. Thromb J (2005) 1.20
The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. J Neurosci (2010) 1.18
Androgen treatment and muscle strength in elderly men: A meta-analysis. J Am Geriatr Soc (2006) 1.17
Hormonal regulation of longevity in mammals. Ageing Res Rev (2007) 1.15
Stroke risk in women: the role of menopause and hormone therapy. Lancet Neurol (2012) 1.10
Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause (2013) 1.08
Cerebral ischemic stroke: is gender important? J Cereb Blood Flow Metab (2013) 1.07
Stroke in women: disparities and outcomes. Curr Cardiol Rep (2010) 1.07
Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol (2009) 1.07
Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med (2009) 1.07
Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol (2011) 1.03
Evaluation of estrogenic activity of licorice species in comparison with hops used in botanicals for menopausal symptoms. PLoS One (2013) 1.01
Sexual dimorphism in ischemic stroke: lessons from the laboratory. Womens Health (Lond Engl) (2011) 1.00
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause (2013) 1.00
Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc (2010) 1.00
Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging (2010) 1.00
Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One (2009) 0.99
Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke. Horm Behav (2012) 0.99
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke (2008) 0.97
Sex differences in ischemic stroke sensitivity are influenced by gonadal hormones, not by sex chromosome complement. J Cereb Blood Flow Metab (2014) 0.97
Poverty is a risk factor for osteoporotic fractures. Osteoporos Int (2008) 0.96
Estradiol is a potent protective, restorative, and trophic factor after brain injury. Semin Reprod Med (2009) 0.96
Sex-specific responses to stroke. Future Neurol (2010) 0.96
Effect of extended-term estrogen on voiding in a postpartum ovariectomized rat model. Can Urol Assoc J (2007) 0.96
Neuroprotective actions of selective estrogen receptor modulators. Psychoneuroendocrinology (2009) 0.95
The effects of estrogen in ischemic stroke. Transl Stroke Res (2012) 0.95
Sex differences in the risk of stroke and HbA(1c) among diabetic patients. Diabetologia (2014) 0.95
Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. Neurology (2014) 0.94
Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol (2010) 0.94
A second chance for hormone replacement therapy? EMBO Rep (2003) 0.93
Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography. JAMA Psychiatry (2014) 0.92
Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline. Behav Neurosci (2012) 0.92
Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med (2010) 0.92
Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J (2013) 0.92
The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric (2012) 0.91
The medical management of menopause: a four-country comparison care in urban areas. Maturitas (2008) 0.91
Cardiovascular diseases in American women. Nutr Metab Cardiovasc Dis (2010) 0.90
Relationship of hypertension, blood pressure, and blood pressure control with white matter abnormalities in the Women's Health Initiative Memory Study (WHIMS)-MRI trial. J Clin Hypertens (Greenwich) (2010) 0.90
Soy phytoestrogens are neuroprotective against stroke-like injury in vitro. Neuroscience (2008) 0.90
A new approach to understanding the molecular mechanisms through which estrogens affect cognition. Biochim Biophys Acta (2009) 0.89
Window of opportunity: estrogen as a treatment for ischemic stroke. Brain Res (2013) 0.88
Effects of chronic and acute oestrogen replacement therapy in aged animals after experimental stroke. J Neuroendocrinol (2012) 0.88
The effect of ovariectomy and estrogen on penetrating brain arterioles and blood-brain barrier permeability. Microcirculation (2009) 0.87
PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol (2013) 0.87
A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study. Menopause (2011) 0.87
Mnemonic effects of progesterone to mice require formation of 3alpha,5alpha-THP. Neuroreport (2010) 0.87
Serum fatty acids and incidence of ischemic stroke among postmenopausal women. Stroke (2013) 0.87
Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. Ann Epidemiol (2014) 0.87
The membrane estrogen receptor ligand STX rapidly enhances GABAergic signaling in NPY/AgRP neurons: role in mediating the anorexigenic effects of 17β-estradiol. Am J Physiol Endocrinol Metab (2013) 0.86
Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. Osteoporos Int (2005) 0.86
Postmenopausal hormone therapy and incident urinary incontinence in middle-aged women. Am J Obstet Gynecol (2008) 0.86
The effects of long-term treatment with estradiol and medroxyprogesterone acetate on tyrosine hydroxylase fibers and neuron number in the medial prefrontal cortex of aged female rats. Endocrinology (2012) 0.86
Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. Neuropsychopharmacology (2013) 0.85
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev (2004) 7.57
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med (2004) 6.77
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A (2008) 5.71
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care (2011) 5.50
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA (2003) 4.72
Genome-wide DNA replication profile for Drosophila melanogaster: a link between transcription and replication timing. Nat Genet (2002) 4.68
Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol (2010) 4.61
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2004) 3.96
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev (2004) 3.74
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med (2004) 3.59
Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol (2002) 3.54
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol (2012) 3.23
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res (2011) 3.01
Midlife risk factors and healthy survival in men. JAMA (2006) 3.00
The Next PAGE in understanding complex traits: design for the analysis of Population Architecture Using Genetics and Epidemiology (PAGE) Study. Am J Epidemiol (2011) 2.98